These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29374487)

  • 1. Current trials for frontline therapy of mantle cell lymphoma.
    Steiner RE; Romaguera J; Wang M
    J Hematol Oncol; 2018 Jan; 11(1):13. PubMed ID: 29374487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
    Nabrinsky E; Danilov AV; Koller PB
    Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapies in mantle cell lymphoma.
    Hanel W; Epperla N
    J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.
    Klener P
    Expert Opin Ther Targets; 2020 Oct; 24(10):1029-1045. PubMed ID: 32842810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
    Nastoupil LJ; Koff JL; Flowers CR
    Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.
    Kahl BS; Dreyling M; Gordon LI; Quintanilla-Martinez L; Sotomayor EM
    Leuk Lymphoma; 2017 Jul; 58(7):1561-1569. PubMed ID: 28140709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-chemotherapy Options for Newly Diagnosed Mantle Cell Lymphoma.
    Takiar R; Phillips T
    Curr Treat Options Oncol; 2021 Sep; 22(11):98. PubMed ID: 34524546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mantle cell lymphoma: evolving management strategies.
    Campo E; Rule S
    Blood; 2015 Jan; 125(1):48-55. PubMed ID: 25499451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mantle cell lymphoma: are current therapies changing the course of disease?
    Geisler C
    Curr Oncol Rep; 2009 Sep; 11(5):371-7. PubMed ID: 19679012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma.
    Munger CM; Hegde GV; Weisenburger DD; Vose JM; Joshi SS
    Cancer Immunol Immunother; 2012 Oct; 61(10):1819-32. PubMed ID: 22441656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal management of mantle cell lymphoma in the primary setting.
    Tang C; Kuruvilla J
    Expert Rev Hematol; 2019 Sep; 12(9):715-721. PubMed ID: 31268728
    [No Abstract]   [Full Text] [Related]  

  • 15. Dismantling relapsed/refractory mantle cell lymphoma.
    Ryan CE; Kumar A
    Blood Rev; 2024 Sep; 67():101221. PubMed ID: 38906740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Update on treatment strategies for mantle cell lymphoma].
    Fukuhara S
    Rinsho Ketsueki; 2024; 65(9):1012-1018. PubMed ID: 39358255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
    Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA
    Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
    Wang JF; Wang Y
    Expert Rev Hematol; 2024 Oct; 17(10):651-659. PubMed ID: 39109468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequencing of Novel Therapies for Mantle Cell Lymphoma.
    Romancik JT; Cohen JB
    Curr Treat Options Oncol; 2021 Nov; 22(12):118. PubMed ID: 34812968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.